Breaking Finance News

Idera Pharmaceuticals Announces Positive Phase I Trial Data

Idera Pharmaceuticals, (NASDAQ: IDRA) a Cambridge, Massachusetts based biopharma firm, announced results of a Phase 1 clinical trial of its experimental compound, IMO-8400. The company reported that it was well-tolerated at all dosage levels.

According to the company press release, IMO-8400 is a first of its kind drug developed for uses in autoimmune and inflammatory diseases. It was administered to healthy subjects at various dosage levels for four weeks.

“We are very pleased with the safety and tolerability of IMO-8400 in this trial. Further, IMO-8400 showed strong and sustained inhibition of TLR7-, 8-, and 9- mediated cytokine induction,” said Robert D. Arbeit, M.D., Vice President of Clinical Development. “Based on these encouraging results, we have initiated a randomized, double-blind, placebo-controlled Phase 2 trial of IMO-8400 in patients with psoriasis to evaluate PASI score improvement over a 12-week treatment period at three dose levels.”

READ: Raptor Pharmaceuticals up 26 Percent on FDA Approval

Phase 2 trials are taking place in patients with moderate to severe plaque Psoriasis and are expected to be announced by the end of 2013 and will inform the company’s decisions regarding later stage clinical developments.

[stock-tools exchange="NASDAQ" symbol="IDRA" image_height="230" image_width="350"]

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.